Table 1. Patients’ Characteristics UPN .... | American Society of Hematology

Table 1.

Patients’ Characteristics

UPN	Stage	BCR/ABL	Treatment	Mobilization
1	ECP	b3a2	Hydroxyurea	Cytox/G
2	ECP	b3a2	IFN-α	MAC/G
3	ECP	b3a2	Hydroxyurea/IFN-α	No
4	ECP	b3a2	Hydroxyurea	Cytox/G
5	LCP	b2a2	Hydroxyurea	MAC/G
6	LCP	b2a2	Hydroxyurea/IFN-α	MAC/G
7	LCP	b3a2	IFN-α	Cytox/G
8	LCP	b3a2	IFN-α	No
9	AP	b3a2	Hydroxyurea/IFN-α	MAC/G
10	AP	b3a2	Hydroxyurea	No
11	AP	b3a2	IFN-α	No

UPN	Stage	BCR/ABL	Treatment	Mobilization
1	ECP	b3a2	Hydroxyurea	Cytox/G
2	ECP	b3a2	IFN-α	MAC/G
3	ECP	b3a2	Hydroxyurea/IFN-α	No
4	ECP	b3a2	Hydroxyurea	Cytox/G
5	LCP	b2a2	Hydroxyurea	MAC/G
6	LCP	b2a2	Hydroxyurea/IFN-α	MAC/G
7	LCP	b3a2	IFN-α	Cytox/G
8	LCP	b3a2	IFN-α	No
9	AP	b3a2	Hydroxyurea/IFN-α	MAC/G
10	AP	b3a2	Hydroxyurea	No
11	AP	b3a2	IFN-α	No

BCR/ABL gene rearrangements were determined by RT-PCR and Southern blotting. “b3a3” indicates that the RT-PCR product hybridized with the probe (B3A2) spanning abl exon 2 and bcr exon 3, whereas “b2a2” means rearrangement between abl exon 2 and bcr exon 2.

Abbreviations: MAC-G, mitoxantrone (8 mg/m² on days 1 and 2), cytosine-arabinoside (1,000 mg/m² twice daily on days 1 and 2), cyclophosphamide (4 g/m² on day 1), and G-CSF 5 μg/kg/d starting on day +5; Cytox/G, cyclophosphamide (4 g/m²) followed by G-CSF at 5 μg/kg/d starting on day +5; ND, not done.

View Large

This Feature Is Available To Subscribers Only